REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo tested to fight back against tough lymphomas
Disease control Recruiting nowThis study is testing whether combining an existing immunotherapy drug (pembrolizumab) with a vitamin A-based drug (ATRA) can help control lymphoma that has come back or stopped responding to standard treatments. It will enroll 24 adults with specific types of Hodgkin or B-cell n…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Rita Assi • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New combo trial aims to reawaken immune system against stubborn lymphomas
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a two-drug combination for people with B-cell lymphomas that have come back or stopped responding to other treatments. The treatment pairs an immunotherapy drug (nivolumab) with a pill (ASTX727) that may help the immun…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Radioactive 'Warhead' targets tough hodgkin lymphoma in new transplant strategy
Disease control Recruiting nowThis study is testing a new two-part treatment for Hodgkin lymphoma that has not responded to or has returned after initial therapy. First, a radioactive antibody is given to seek out and kill cancer cells. Then, high-dose chemotherapy and a patient's own stem cells are used to t…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New cancer drug enters first human trials for patients out of options
Disease control Recruiting nowThis is a first-in-human study to test the safety and find the right dose of a new drug called HCB301. It is for adults with advanced solid tumors or Hodgkin lymphoma that have not responded to standard treatments. The main goals are to see what side effects occur and how the bod…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: FBD Biologics Limited • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC